3.
NSCLC组织中CDC25A表达与临床的关系
Expression of CDC25Ain NSCLC and its correlation with the clinicopathological parameters
| Clinicopathological features | n | CDC25A | χ2 | P | |
| Positive [n(%)] | Negative [n(%)] | ||||
| Age (year) | 1.55 | 0.21 | |||
| ≥60 | 33 | 27 (81.8) | 6 (18.2) | ||
| < 60 | 11 | 7 (63.6) | 4 (36.4) | ||
| Sex | 0.20 | 0.65 | |||
| Male | 29 | 23 (79.3) | 6 (20.7) | ||
| Female | 15 | 11 (73.3) | 4 (26.7) | ||
| Pathological type | 1.63 | 0.20 | |||
| Adenocarcinoma | 23 | 16 (69.6) | 7 (30.4) | ||
| Squamous cell carcinoma | 21 | 18 (85.7) | 3 (14.3) | ||
| Smoking | 4.92 | 0.03 | |||
| Yes | 23 | 20 (87.0) | 3 (13.0) | ||
| No | 21 | 12 (57.1) | 9 (42.9) | ||
| Differentiation degree | 2.81 | 0.25 | |||
| Grade Ⅰ | 13 | 8 (61.5) | 5 (38.5) | ||
| Grade Ⅱ | 27 | 23 (85.2) | 4 (14.8) | ||
| Grade Ⅲ | 4 | 3 (75.0) | 1 (25.0) | ||
| Lymph node metastasis | 4.74 | 0.03 | |||
| Yes | 14 | 8 (57.1) | 6 (42.9) | ||
| No | 30 | 26 (86.7) | 4 (13.3) | ||
| Clinical stages | 0.96 | 0.33 | |||
| Ⅰ-Ⅱ | 39 | 31 (79.5) | 8 (20.5) | ||
| Ⅲ-Ⅳ | 5 | 3 (60.0) | 2 (40.0) | ||